The P2X7R-antagonist AFC-5128 ameliorates chronic experimental autoimmune encephalomyelitis in a preventive and therapeutic paradigm
The treatment of EAE mice with AFC-5128 improved acute and chronic EAE in different treatment paradigms, with positive effects on histological markers and slight modulation of microglial marker expression. Mechanistically, calcium influx of microglia was reduced following AFC-5128 treatment, which implies the ability of AFC-5128 to stabilize calcium homeostasis. Therefore, therapeutic inhibition of P2X7R via AFC-5128 has the potential for translation into a treatment of both relapsing and progressive forms of multiple sclerosis.
Authors
- Katharina Klöster
- Ingo Kleiter (ORCID: https://orcid.org/0000-0002-8249-4408)
- Bert Klebl (ORCID: https://orcid.org/0000-0001-5475-9053)
- Neele Heitmann (ORCID: https://orcid.org/0009-0005-5519-4695)
- Michael Hamacher
- Klaus Dinkel
- Ralf Gold (ORCID: https://orcid.org/0000-0002-7223-3052)
- Verian Bader (ORCID: https://orcid.org/0000-0001-5260-4728)
- Simon Faissner (ORCID: https://orcid.org/0000-0002-3412-762X)
- Xiomara Pedreiturria (ORCID: https://orcid.org/0000-0002-3024-3826)
- Konstanze F. Winklhofer (ORCID: https://orcid.org/0000-0002-7256-8231)
- Robert Hoffrogge
- Anna Karachunskaya
Institutions
- Lund University (SE)
- Institut für Forschung und Transfer (DE)
- Affimed Therapeutics (Germany) (DE)
- Zentrum Überleben (DE)
- Lead Discovery Center (Germany) (DE)
- St. Josef-Hospital (DE)
- Ruhr University Bochum (DE)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-04-16
- DOI
- https://doi.org/10.3389/fimmu.2025.1554999
- Primary Topic
- Adenosine and Purinergic Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.00